109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
免疫检查点抑制剂在结直肠癌治疗中的应用进展
Authors Li J, Fu T, Wen Z, Liang J, Qiu Y, Li K, Yang J, Tong Y, Cai H
Received 3 July 2025
Accepted for publication 30 September 2025
Published 15 October 2025 Volume 2025:18 Pages 1159—1168
DOI https://doi.org/10.2147/OTT.S551204
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr John Maher
Jianing Li,1 Tong Fu,2 Zhu Wen,3 Jiahao Liang,1 Yanzhi Qiu,1 Kaiqing Li,1 Jiamin Yang,1 Ying Tong,3 Hongbo Cai3
1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China; 2Department of Psychology, Brandeis University, Waltham, MA, USA; 3First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China
Correspondence: Ying Tong, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China, Email tongying@hljucm.edu.cn Hongbo Cai, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China, Email caihongbo@hljucm.edu.cn
Purpose: Colorectal cancer (CRC) is a highly prevalent malignant tumor worldwide, and the emergence of immune checkpoint inhibitors (ICIs) has changed CRC immunotherapy. This systematic review aims to provide a comprehensive overview of registered clinical trials on ICIs in CRC worldwide, with a focus on major molecular targets, combination therapy strategies, geographic distribution patterns, and future directions for precision immunotherapy.
Methods: All clinical trials related to ICIs in CRC were retrieved. Trials were screened according to inclusion and exclusion criteria, and core information such as trial phase, conducting country, mechanism targets, and combination therapy, was systematically organized for retrospective and trend analyses.
Results: A total of 1,479 eligible clinical trials were included. There has been a steady increase in the number of registered trials, with Phase II trials being the most numerous. The United States and China lead globally in the number of trials reported. Key research targets included PD-1, PD-L1, CTLA-4, and molecules related to the tumor microenvironment. Combination therapies involving ICIs, anti-angiogenic agents, and targeted drugs across multiple pathways emerged as a new research focus.
Conclusion: ICIs have driven the development of precision immunotherapy for CRC, and multi-target combination therapies hold promise for improving outcomes. However, clinical translation and efficacy improvements remain challenging. Future studies should focus on the mechanisms involved and accumulating clinical data to guide more effective immunotherapy strategies.
Keywords: colorectal cancer, immune checkpoint inhibitors, clinical trials, combination therapy, tumor microenvironment
1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China; 2Department of Psychology, Brandeis University, Waltham, MA, USA; 3First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China
Correspondence: Ying Tong, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China, Email tongying@hljucm.edu.cn Hongbo Cai, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, People’s Republic of China, Email caihongbo@hljucm.edu.cn
Purpose: Colorectal cancer (CRC) is a highly prevalent malignant tumor worldwide, and the emergence of immune checkpoint inhibitors (ICIs) has changed CRC immunotherapy. This systematic review aims to provide a comprehensive overview of registered clinical trials on ICIs in CRC worldwide, with a focus on major molecular targets, combination therapy strategies, geographic distribution patterns, and future directions for precision immunotherapy.
Methods: All clinical trials related to ICIs in CRC were retrieved. Trials were screened according to inclusion and exclusion criteria, and core information such as trial phase, conducting country, mechanism targets, and combination therapy, was systematically organized for retrospective and trend analyses.
Results: A total of 1,479 eligible clinical trials were included. There has been a steady increase in the number of registered trials, with Phase II trials being the most numerous. The United States and China lead globally in the number of trials reported. Key research targets included PD-1, PD-L1, CTLA-4, and molecules related to the tumor microenvironment. Combination therapies involving ICIs, anti-angiogenic agents, and targeted drugs across multiple pathways emerged as a new research focus.
Conclusion: ICIs have driven the development of precision immunotherapy for CRC, and multi-target combination therapies hold promise for improving outcomes. However, clinical translation and efficacy improvements remain challenging. Future studies should focus on the mechanisms involved and accumulating clinical data to guide more effective immunotherapy strategies.
Keywords: colorectal cancer, immune checkpoint inhibitors, clinical trials, combination therapy, tumor microenvironment